Darrah, Rebecca J <br/><br/>
AGTR2 absence or antagonism prevents cystic fibrosis pulmonary manifestations.  [electronic resource] 

 -  Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society  01 2019 
 - 127-134 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1873-5010 
<br/><br/><label>Standard No.: </label>10.1016/j.jcf.2018.05.013  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiotensin II Type 2 Receptor Blockers--pharmacology<br/>Animals<br/>Child<br/>Cystic Fibrosis--complications<br/>DNA--genetics<br/>DNA Mutational Analysis<br/>Disease Models, Animal<br/>Female<br/>Follow-Up Studies<br/>Forced Expiratory Flow Rates--physiology<br/>Genotype<br/>Humans<br/>Imidazoles--pharmacology<br/>Lung--physiopathology<br/>Lung Diseases--etiology<br/>Male<br/>Mice<br/>Mice, Knockout<br/>Mutation<br/>Pyridines--pharmacology<br/>Receptor, Angiotensin, Type 2--drug effects<br/>Retrospective Studies